Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
There are MDR pathogens, and there is carbapenem-resistant A. baumannii, aka CRAB. This surely must be one of the most formidable bacterial organisms. It has resistance mechanisms second to none. When found in patients, it is very difficult to eradicate and extremely difficult to get rid off, once established in Continue reading Treating Serious CRAB Infections
Regulatory and development status of Olorofim, a novel antifungal. Continue reading OLOROFIM in a TIGHT SPOT
A recent paper by Thabit describes a curious finding [1]. The authors measured total and free (i.e., nonprotein-bound) eravacycline levels at ascending doses in a mouse model. They found strikingly small increases in free drug levels when titrating up total doses. The effect was rather dramatic: an increase in protein binding from 12% Continue reading Timely New Information on Next-Generation Tetracyclines – Part 2: Eravacycline and Protein Binding